Literature DB >> 19078167

Chlamydia trachomatis Can Persist in Joint Tissue After Antibiotic Treatment in Chronic Reiter's Syndrome / Reactive Arthritis.

A M Beutler1, A P Hudson, J A Whittum-Hudson, W A Salameh, H C Gerard, P J Branigan, H R Schumacher.   

Abstract

Considerable evidence suggests that viable Chlamydia trachomatis are present in joint tissues of patients with Reiter's syndrome/reactive arthritis (RS/ReA), but the use of antibiotics to treat such patients remains controversial. We investigated the continued presence of chlamydia in synovial tissues of patients with RS/ReA; these patients had been treated with antibiotics for relatively extended periods, had shown clinical improvement, but had persistent active disease. Knee synovial tissue was obtained from two patients with RS/ReA and two controls with osteoarthritis (OA). Each sample was screened for chlamydia by culture, direct fluorescent antibody assay (DFA), in situ hybridization (ISH), and polymerase chain reaction (PCR).Synovial tissues from antibiotic-treated RS/ReA patients were negative for chlamydia when analyzed by culture and DFA, but positive when analyzed by ISH for chlamydial RNA and by PCR for chlamydial DNA. Samples from OA patients were negative by all screening methods. Thus, antibiotic treatment does not appear to easily eradicate chlamydia from the joints of RS/ReA patients. Rather, the organism can persist in synovial tissue in a form not detectable by routine laboratory screening methods. Further studies are needed to determine whether antibiotic regimens other than those used here can eradicate synovial chlamydia and to determine how this relates to disease activity. Optimal therapy for patients with RS/ ReA is therefore not yet clear.

Entities:  

Year:  1997        PMID: 19078167     DOI: 10.1097/00124743-199706000-00001

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  5 in total

Review 1.  Bacteria-Triggered reactive arthritis: implications for antibacterial treatment.

Authors:  A Toivanen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.

Authors:  Udaya S Toti; Bharath R Guru; Mirabela Hali; Christopher M McPharlin; Susan M Wykes; Jayanth Panyam; Judith A Whittum-Hudson
Journal:  Biomaterials       Date:  2011-06-08       Impact factor: 12.479

3.  Identification of oral bacterial DNA in synovial fluid of patients with arthritis with native and failed prosthetic joints.

Authors:  Stéphanie Témoin; Alia Chakaki; Ali Askari; Ahmed El-Halaby; Steven Fitzgerald; Randall E Marcus; Yiping W Han; Nabil F Bissada
Journal:  J Clin Rheumatol       Date:  2012-04       Impact factor: 3.517

4.  Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial.

Authors:  N Putschky; H-G Pott; J G Kuipers; H Zeidler; M Hammer; J Wollenhaupt
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

5.  Chronic Lyme Disease and Co-infections: Differential Diagnosis.

Authors:  Walter Berghoff
Journal:  Open Neurol J       Date:  2012-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.